TECVAYLI DIN 02539764
Status: Marketed
Holder: JANSSEN INC
Health Canada record
| Active ingredient(s) | TECLISTAMAB 153 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FX24 TECLISTAMAB |
|---|
| Original market date | 20-Oct-2023 |
|---|
| Current status date | 20-Oct-2023 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TECLISTAMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02539756 | TECVAYLI | JANSSEN INC | Solution | TECLISTAMAB 30 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 31304 | 2023-07-26 | New Drug Submission (NDS) | |
Request a quote for TECVAYLI
How to read a Canadian DIN record